error fb Gplus IN twitter down-arrow Email Phone Check-Mark padlock circle_arrow minus plus play_btn close Clipboard_Icon Shopping-Cart_Icon Speech_Bubble_Icon Stethoscope_Icon pharmacists menu left-arrow right-arrow facebook search cart

About Dexcom

Dexcom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world.


Comprehend the needs of people affected by diabetes.

Serve with integrity

Act in the best interest of our community.

Think big

Use technology to revolutionize diabetes care.

Be dependable

Inspire confidence within our community and in one another.

Our history with CGM

  1. Dexcom G6 CGM Granted Market Authorization

    The FDA permitted the marketing of the Dexcom G6 integrated continuous glucose monitoring (iCGM) system for determining glucose (sugar) levels in children aged two years and older and adults with diabetes. The Dexcom G6 is indicated by the FDA for use as both a standalone CGM and for integration into automated insulin dosing (AID) systems. 

    Learn More
  2. Dexcom Receives FDA Approval of G5 Mobile App for Android Devices

    Android users now have access to the free app for the Dexcom G5 Mobile CGM System. At the time, Dexcom G5 Mobile CGM System was the first and only CGM platform available for Android in the United States.

  3. The Dexcom G5 Mobile CGM System is approved under Medicare

    Centers for Medicare & Medicaid Services (CMS) Classify Therapeutic Continuous Glucose Monitors (CGM) as "Durable Medical Equipment". Dexcom was the first CGM system that falls within this classification.

  4. The Non-Adjunctive Label for the Dexcom G5 Mobile CGM System is approved by the FDA Advisory Committee

    The proposed non-adjunctive indication for the Dexcom G5 Mobile CGM system is approved by the FDA. This indication designates the G5 Mobile CGM system as a replacement to fingerstick glucose testing for diabetes treatment decisions.

  5. sensor talks to cgm system

    Dexcom G5 Mobile CGM System launched

    The Dexcom G5 Mobile CGM System became the first and only fully mobile CGM system to allow adults and children as young as two years old the convenience of monitoring their glucose levels from a compatible smart device. It also gave patients the option to safely share their glucose data with others.

  6. Dexcom G4 PLATINUM CGM System with Share launched

    The Share feature for the G4 PLATINUM CGM System gave patients the option to share their glucose information with up to five followers through Dexcom Share and Follower apps on their smart devices via a secure wireless connection.

  7. Dexcom G4 PLATINUM System launched

    The G4 PLATINUM's overall accuracy and ease of use set a new standard for commercially available CGMs, making the Dexcom G4 PLATINUM the most-advanced CGM system available at the time.

  8. dexcom seven plus device

    Dexcom SEVEN® PLUS CGM System launched

    The SEVEN® PLUS System launched as Dexcom’s third generation device designed to help people with diabetes better manage their glucose levels.

  9. JDRF landmark study in CGM

    Study data presented by the Juvenile Diabetes Research Foundation (JDRF) at the 44th annual meeting of the European Association for the Study of Diabetes (EASD) showed the use of CGM to be effective in the management of type 1 diabetes.

  10. SEVEN® System launched

    Dexcom launched the SEVEN® CGM System, the first CGM system approved for up to seven days of continual use.

  11. STS CGM System launched

    Dexcom launched the first generation continuous glucose monitor designed to help people with diabetes more conveniently and effectively manage their blood sugar levels.

  12. Dexcom announced its IPO

    The initial public offering (IPO) for Dexcom was announced on the NASDAQ Stock Market under DXCM.

  13. Short-term sensor

    Dexcom's short-term sensor program was created.
  14. Research on long-term continuous glucose sensing

    Three generations of Dexcom’s long-term implantable sensors were developed and studied in humans.

  15. Dexcom was founded

    Dexcom was founded based on the groundbreaking research of Dr. Stuart J. Updike and George P. Hicks in 1967—implantable, long-performing glucose sensors that the body would not reject. Dr. Updike joined Dexcom that year to continue CGM innovation.